Literature DB >> 24161884

Relation between genotype and left-ventricular dilatation in patients with Marfan syndrome.

Jan J J Aalberts1, J Peter van Tintelen, Lilian J Meijboom, Annette Polko, Jan D H Jongbloed, Henriette van der Wal, Gerard Pals, Jan Osinga, Janneke Timmermans, Julie de Backer, Marian K Bakker, Dirk J van Veldhuisen, Robert M W Hofstra, Barbara J M Mulder, Maarten P van den Berg.   

Abstract

Cardiovascular manifestations in patients with Marfan syndrome (MFS) are related to aortic and valvular abnormalities. However, dilatation of the left ventricle (LV) can occur, even in the absence of aortic surgery or valvular abnormalities. We evaluated genetic characteristics of patients with MFS with LV dilatation. One hundred eighty-two patients fulfilling the MFS criteria, without valvular abnormalities or previous aortic surgery, with a complete FBN1 analysis, were studied. FBN1 mutations were identified in over 81% of patients. Twenty-nine patients (16%) demonstrated LV dilatation (LV end diastolic diameter corrected for age and body surface area >112%). FBN1-positive patients carrying a non-missense mutation more often had LV dilatation than missense mutation carriers (14/74 versus 5/75; p<0.05). Finally, FBN1-negative MFS patients significantly more often demonstrated LV dilatation than FBN1-positive patients (10/33 versus 19/149; p<0.05). It is concluded that LV dilatation in MFS patients is more often seen in patients with a non-missense mutation and in those patients without an FBN1 mutation. Therefore physicians should be aware of the possibility of LV dilatation in these patients even in the absence of valvular pathology.
© 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  DHPLC; FBN1-mutation; FBNI; Genetics; Genotype–phenotype relation; LV; LVEDD; Left ventricular dilatation; M-mode; MFS; MLPA; Marfan syndrome; SD; TGFBR1; TGFBR2; TGFβ; denaturing high performance liquid chromatography; fibrillin-1 gene; left ventricle; left ventricular end diastolic dimension; motion mode; multiplex ligation-dependent probe amplification; standard deviation; transforming growth factor beta; transforming growth factor-β receptor 1 gene; transforming growth factor-β receptor 2 gene

Mesh:

Substances:

Year:  2013        PMID: 24161884     DOI: 10.1016/j.gene.2013.10.033

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  12 in total

1.  Mutation analysis of FBN1 gene in two Chinese families with congenital ectopia lentis in northern China.

Authors:  Su-Zhen Tang; Ya-Ning Liu; Shao-Hua Hu; Hao Chen; Hui Zhao; Xue-Mei Feng; Xiao-Jing Pan; Peng Chen
Journal:  Int J Ophthalmol       Date:  2019-11-18       Impact factor: 1.779

2.  Frequency of Ventricular Arrhythmias and Other Rhythm Abnormalities in Children and Young Adults With the Marfan Syndrome.

Authors:  Douglas Y Mah; Lynn A Sleeper; Jane E Crosson; Richard J Czosek; Barry A Love; Brian W McCrindle; Laura Muiño-Mosquera; Aaron K Olson; Thomas A Pilcher; Elif Seda Selamet Tierney; Maully J Shah; Stephanie B Wechsler; Luciana T Young; Ronald V Lacro
Journal:  Am J Cardiol       Date:  2018-07-17       Impact factor: 2.778

3.  Non-aortic cardiovascular disease in Marfan syndrome: a nationwide epidemiological study.

Authors:  Niels H Andersen; Kristian A Groth; Agnethe Berglund; Hanne Hove; Claus H Gravholt; Kirstine Stochholm
Journal:  Clin Res Cardiol       Date:  2021-04-22       Impact factor: 5.460

4.  The effect of losartan therapy on ventricular function in Marfan patients with haploinsufficient or dominant negative FBN1 mutations.

Authors:  A W den Hartog; R Franken; M P van den Berg; A H Zwinderman; J Timmermans; A J Scholte; V de Waard; A M Spijkerboer; G Pals; B J M Mulder; M Groenink
Journal:  Neth Heart J       Date:  2016-11       Impact factor: 2.380

5.  Ventricular-Vascular Coupling in Marfan and Non-Marfan Aortopathies.

Authors:  Farina Loeper; Jantine Oosterhof; Mark van den Dorpel; Denise van der Linde; Yaxin Lu; Elizabeth Robertson; Brett Hambly; Richmond Jeremy
Journal:  J Am Heart Assoc       Date:  2016-11-16       Impact factor: 5.501

6.  Identification of Novel Causal FBN1 Mutations in Pedigrees of Marfan Syndrome.

Authors:  Yueli Wang; Xiaoyan Li; Rongjuan Li; Ya Yang; Jie Du
Journal:  Int J Genomics       Date:  2018-04-17       Impact factor: 2.326

Review 7.  The Potential Beneficial Effects of Resveratrol on Cardiovascular Complications in Marfan Syndrome Patients⁻Insights from Rodent-Based Animal Studies.

Authors:  Mitzi M van Andel; Maarten Groenink; Aeilko H Zwinderman; Barbara J M Mulder; Vivian de Waard
Journal:  Int J Mol Sci       Date:  2019-03-05       Impact factor: 5.923

8.  Next-generation sequencing for diagnosis of thoracic aortic aneurysms and dissections: diagnostic yield, novel mutations and genotype phenotype correlations.

Authors:  J K Poninska; Z T Bilinska; M Franaszczyk; E Michalak; M Rydzanicz; E Szpakowski; A Pollak; B Milanowska; G Truszkowska; P Chmielewski; A Sioma; H Janaszek-Sitkowska; A Klisiewicz; I Michalowska; M Makowiecka-Ciesla; P Kolsut; P Stawinski; B Foss-Nieradko; M Szperl; J Grzybowski; P Hoffman; A Januszewicz; M Kusmierczyk; R Ploski
Journal:  J Transl Med       Date:  2016-05-04       Impact factor: 5.531

9.  Heart failure and sudden cardiac death in heritable thoracic aortic disease caused by pathogenic variants in the SMAD3 gene.

Authors:  Julie De Backer; Alan C Braverman
Journal:  Mol Genet Genomic Med       Date:  2018-05-01       Impact factor: 2.183

10.  Myocardial disease and ventricular arrhythmia in Marfan syndrome: a prospective study.

Authors:  Laura Muiño-Mosquera; Hans De Wilde; Daniel Devos; Danilo Babin; Luc Jordaens; Anthony Demolder; Katya De Groote; Daniel De Wolf; Julie De Backer
Journal:  Orphanet J Rare Dis       Date:  2020-10-23       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.